Adjuvant and neoadjuvant radiotherapy for bladder cancer: Revisited

Future Oncology

Volumn 6, Issue 7, 2010, Pages 1177-1191

  Zaghloul, Mohamed Saad ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

adaptive radiotherapy; adjuvant radiotherapy; bladder cancer; IGRT; neoadjuvant radiotherapy prognostic factor; radical cystectomy; radiotherapy technique

Indexed keywords

BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CYSTECTOMY; DISTANT METASTASIS; HUMAN; OUTCOME ASSESSMENT; PELVIS LYMPH NODE; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REVIEW; SURVIVAL RATE; ADJUVANT THERAPY; CLINICAL TRIAL (TOPIC); MULTIMODALITY CANCER THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); URINARY BLADDER NEOPLASMS;

ADJUVANTS, PHARMACEUTIC; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; NEOADJUVANT THERAPY; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINARY BLADDER NEOPLASMS;

PHARMACEUTICAL VEHICLES AND ADDITIVES;

EID: 77954676300     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.82     Document Type: Review

References (117)

1. Parkin DM, Bray F, Ferlay J, et al.: Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005).
2. Stein JP, Lieskovsky G, Cote R, et al.: Radical cystectomy in treatment of invasive bladder cancer: long term results in 1054 patients. J. Clin. Oncol. 19, 666-675 (2001).
3. Zaghloul MS, Nouh A, Moneer M, et al.: Time-trend in epidemiological and pathological features of schistosoma-associated bladder cancer. J. Egypt. Natl Canc. Inst. 20(2), 168-174 (2008).
4. Murthy V, Zaghloul MS: Adjuvant radiotherapy in bladder cancer: time to take a fresh look? Urol. Oncol. 25(4), 353-354 (2006).
5. Ghoneim MA, El Mekresh MM, el Baz MA, et al.: Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1026 cases. J. Urol. 158, 393-399 (1997).
6. Ghoneim MA, Abdel-Latif M, el-Mekresh M, et al.: Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J. Urol. 180(1), 121-127 (2008).
7. Smith JA Jr, Whitmore WF Jr: Regional lymph node metastasis from bladder cancer. J. Urol. 126(5), 591-593 (1981).
8. Vazina A, Dugi D, Shariat SF, et al.: Stage specific lymph node metastasis mapping in radical cystectomy specimens. J. Urol. 171(5), 1830-1834 (2004).
9. Hurle R, Naspro R: Pelvic lymphadenectomy during radical cystectomy: a review of the literature. Surg. Oncol. DOI: 10.1016/j. suronc.2009.05.004 (2009) (Epub ahead of print).
10. Nagele U, Anastasiadis AG, Merseburger AS, et al.: Clinical outcome after cystectomy in patients with lymph node-positive bladder cancer. Expert Rev. Anticancer Ther. 6(6), 871-876 (2006).
11. Abdel-Latif M, Abol-Enein H, El-Baz M, Ghoneim MA: Nodal involvement in bladder cancer cases treated with radical cystectomy: incidence and prognosis. J. Urol. 172(1), 85-89 (2004).
12. Herr HW: Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy. Urology 61(1), 105-108 (2003).
13. Leissner J, Hohenfellner R, Thüroff JW, et al.: Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int. 85(7), 817-823 (2000).
14. Medersbacher S, Hochreiter W, Burkhard F, et al.: Radical cystectomy for bladder cancer today-a homogenous series without neoadjuvant therapy. J. Clin. Oncol. 21, 690-696 (2003).
15. Nishiyama H, Habuchi T, Watanabe J, et al.: Clinical outcome of a large-scale multi-institutional retrospective study for locally advanced bladder cancer. A survey including 1131 patients treated during 1990-2000 in Japan. Eur. Urol. 45, 176-181 (2004).
16. Takahashi A, Tsukamoto T, Tobisu K, et al.: Radical cystectomy for invasive bladder cancer, results of multi-institutional pooled analysis. Jpn. J. Clin. Oncol. 34, 14-19 (2004). (Pubitemid 43115329)
17. Rogers CG, Palapattu GS, Shariat SF, et al.: Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma for the bladder compared with transitional cell carcinoma of the bladder. J. Urol. 175, 2048-2053 (2006).
18. El Mekresh MM, el Baz MA, Abol Enin H, et al.: Primary adenocarcinoma of the urinary bladder. A report of 185 cases. Br. J. Urol. 82, 206-212 (1998).
19. Zaghloul MS, Nouh A, Nazmy M, et al.: Long-term results of primary adenocarcinoma of the urinary bladder. A report on 192 patients. Urol. Oncol. 24, 13-20 (2006).
20. Zaghloul MS, El Baradie M, Nouh MA, et al.: Prognostic index for primary adenocarcinoma of the urinary bladder. Gulf J. Oncol. 1(2), 47-54 (2007).
21. Lughezzani G, Sun M, Jeldres C, et al.: Adenocarcinoma versus urothelial carcinoma of the urinary bladder: comparison between pathologic stage at radical cystectomy and cancer-specific mortality. Urology 75(2), 376-381 (2010).
22. Scosyrev E, Yao J, Messing E: Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment? Urology 73, 822-827 (2009).
23. Ploeg M, Aben KK, Hulsbergen-van de Kaa CA, et al.: Clinical epidemiology of nonurothelial bladder cancer: analysis of The Netherlands Cancer Registry. J. Urol. 183(3), 915-920 (2010).
24. Viewing J, Gschwend JE, Herr HW, et al.: The impact of primary stage on survival in patients with lymph node positive bladder cancer. J. Urol. 161, 72-76 (1999).
25. Leissner J, Ghoneim MA, Abol-Enin H, et al.: Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J. Urol. 171, 139-144 (2004).
26. Poulsen BL, Horn T, Steven K: Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J. Urol. 160, 2015-2020 (1998).
27. Kassouf W, Agarwal PK, Herr HW, et al.: Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J. Clin. Oncol. 26(1), 121-126 (2008).
28. Quek ML, Flanigan RC: The role of lymph node density in bladder cancer prognostication. World J. Urol. 27, 27-32 (2009).
29. Wright JL, Lin DW, Porter MP: The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer 112(11), 2401-2408 (2008).
30. Cheng L, Weaver AL, Leibovich BC, et al.: Predicting the survival of bladder carcinoma patients treated with radical cystectomy. Cancer 88, 2326-2332 (2000).
31. Pollack A, Zagars GK, Dinney CP, et al.: Preoperative radiotherapy for muscle-invasive bladder carcinoma. Long term follow up and prognostic factors for 338 patients. Cancer 74, 2819-2827 (1994).
32. Zaghloul MS, Awwad HK, Omar S, et al.: Postoperative radiotherapy of carcinoma in bilharzial bladder. Improved disease-free survival through improving local control. Int. J. Radiat. Oncol. Biol. Phys. 22, 511-517 (1992).
33. Zaghloul MS: Distant metastasis from bilharzial bladder cancer. Cancer 77, 743-749 (1996).
34. Frazier HA, Robertson JE, Dodge RK, Paulson DF: The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 15, 3993-4001 (1993).
35. Cole CT, Pollack A, Zagars GK, et al.: Local control of muscle invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone. Int. J. Radiat. Oncol. Biol. Phys. 32, 331-340 (1995).
36. Bassi P, Ferrante GD, Piazza N, et al.: Prognostic factors of outcome after radical cystectomy for bladder cancer, a retrospective study of homogenous patient cohort. J. Urol. 161, 1494-1497 (1999).
37. Zaghloul MS, Awwad HK, Soliman O, et al.: Postoperative radiotherapy of carcinoma in bilharzial bladder using a three-fractions per day regimen. Radiother. Oncol. 6, 257-265 (1986).
38. Leisser J, Allhof EP, Hohenfellner R, et al.: Ranking of pelvic lymphadenopathy in therapy and prognosis of carcinoma of the bladder. Akt. Urol. 34, 392-397 (2003). (Pubitemid 37456938)
39. Logothetis CJ, Johnson DE, Chong C, et al.: Adjuvant cyclophosphamide, doxorubicin and cisplatin chemotherapy for bladder cancer: an update. J. Clin. Oncol. 6, 1590-1596 (1988).
40. Lotan Y, Gupta A, Shariat SF, et al.: Lymphovascular invasion is independently associated with overall survival, cause-specific survival and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J. Clin. Oncol. 23, 6533-6539 (2005).
41. Bolenz C, Herrmann E, Bastian PJ, et al.: Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial. BJU Int. DOI: 10.1111/j.1464-410X.2009. 09166.x (2010) (Epub ahead of print).
42. Korokopoulou P, Konstantinidou AE, Kavantzas N, et al.: Morpholmetric microvascular characteristics predict prognosis in superficial and invasive bladder cancer. Virch. Arch. 438, 603-611 (2001).
43. El Sobky E, el Baz M, Gomha M, et al.: Prognostic value of angiogenesis in chistosoma-associated squamous cell carcinoma of the urinary bladder. Urology 60, 69-73 (2002).
44. El Sobky E, el Baz M, Gomha M, et al.: Prognostic significance of angiogenesis in chistosoma-associated adenocarcinoma of the urinary bladder. Br. J. Urol. 89, 126-132 (2002). (Pubitemid 34117780)
45. Offerson BV, Knap MM, Marcussen N, et al.: Intense inflammation in bladder carcinoma is associated with angiogenesis and indicates good prognosis. Br. J. Cancer 87, 1422-1430 (2002).
46. Sagol O, Yorukoglu K, Sis B, et al.: Does angiogenesis predict recurrence in superficial transitional cell carcinoma of the bladder? Urology 57, 895-899 (2001).
47. Shariat SF, Tokunaga H, Zhou J, et al.: p53, p21, pRB and p16 expression predict clinical outcome in cystectomy with bladder cancer. J. Clin. Oncol. 15, 1014-1024 (2004).
48. Logothetis CJ, Xu HJ, Ro JY, et al.: Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J. Natl Cancer Inst. 84, 1256-1261 (1992).
49. Cordon-Cardo C, Wartinger D, Petrylak D, et al.: Altered expression of retinoblastoma gene product: prognostic indicator in bladder cancer. J. Natl Cancer Inst. 84, 1251-1255 (1992).
50. Scosyrev E, Noyes K, Feng C, Messing E: Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 115(1), 68-74 (2009).
51. Ghoneim MA, El Mekresh MM, Mokhtar MA, et al.: A predictive model of survival after radical cystectomy for carcinoma of the bladder. Br. J. Urol. 85, 811-816 (2000).
52. Khaled H, El-Hattab O, Moneim DA, Kassem HA, Morsi A, Sherif G: A prognostic index (bladder prognostic index) for bilharzial-related invasive bladder cancer. Urol. Oncol. 23, 254-260 (2005).
53. International Bladder Cancer Nomogram Consortium: Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J. Clin. Oncol. 24, 3967-3972 (2006).
54. Zaak D, Burger M, Otto W, et al.: Predicting individual outcomes after radical cystectomy: an external validation of current nomograms. BUJ Int. DOI: 10.1111/ j.1464-410X.2009.09138.x (2010) (Epub ahead of print).
55. Senglov L, Kamby C, Lund B, Engelholm SA: Docetaxel and cisplatin in metastatic urothelial cancer. A Phase II study. J. Clin. Oncol. 16, 3392-3397 (1998).
56. Pisters LL, Westney L: The management of locally recurrent invasive bladder cancer following radical cystectomy. Semin. Urol. Oncol. 14(2), 112-119 (1996).
57. Greven KM, Spera JA, Solin LW: Local recurrence after cystectomy alone for bladder carcinoma. Cancer 69, 2767-2770 (1992).
58. Visser O, Nieuwenhuijzen JA, Horenblas S: Local recurrence after cystectomy and survival of patients with bladder cancer: a population based study in greater Amsterdam. J. Urol. 174, 97-102 (2005).
59. Knap MM, Lundbeck F, Overgaard J: Prognostic factors pattern of recurrence and survival in Danish bladder cancer cohort treated with radical cystectomy. Acta Oncol. 42, 160-165 (2003).
60. Volkmer BG, Kuefer R, Bartsch GC Jr, et al.: Oncological followup after radical cystectomy for bladder cancer - is there any benefit? J. Urol. 181(4), 1587-1593 (2009).
61. Gupta NP, Kolla SB, Seth A, et al.: Radical cystectomy for bladder cancer: a single center experience. Indian J. Urol. 24(1), 54-59 (2008).
62. Dhar NB, Jones JS, Reuther AM, et al.: Presentation, location and overall survival of pelvic recurrence after radical cystectomy for transitional cell carcinoma of the bladder. BJU Int. 101(8), 969-972 (2008).
63. Westney OL, Pisters LL, Pettaway CA, et al.: Presentation, methods of diagnosis and therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder. J. Urol. 159(3), 792-795 (1998).
64. Pejcic T, Hadzi-Djokic J, Acimovic M, et al.: Local recurrence of bladder cancer after cystectomy with orthotopic bladder substitution and ileal conduit. Acta Chir. Iugosl. 54(4), 63-67 (2007).
65. Ali-El-Dein B: Oncological outcome after radical cystectomy and orthotopic bladder substitution in women. Eur. J. Surg. Oncol. 35(3), 320-325 (2009).
66. Dhar NB, Campbell SC, Zippe CD, et al.: Outcomes in patients with urothelial carcinoma of the bladder with limited pelvic lymph node dissection. BJU Int. 98(6), 1172-1175 (2006).
67. Hautmann RE, Gschwend JE, de Petriconi RC, et al.: Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J. Urol. 176(2), 486-492 (2006).
68. Hassan J, Cookson M, Smith J, et al.: Patterns of initial transitional cell recurrence in patients after cystectomy. J. Urol. 175, 2054-2057 (2007).
69. Skinner EC, Stein JP, Skinner DG: Surgical benchmarks for the treatment of invasive bladder cancer. Urol. Oncol. 25, 66-71 (2007).
70. Ide H, Kikuchi E, Miyajima A, et al.: The predictability of local recurrence after radical cystectomy in patients with invasive bladder cancer. Jpn. J. Clin. Oncol. 38(5), 360-364 (2008).
71. Rödel C: Current status of radiation therapy and combined-modality treatment for bladder cancer. Strahlenther. Onkol. 180(11), 701-709 (2004).
72. Awwad HK, Hegazy M, Ezzat S, et al.: Cell proliferation of carcinoma in Bilharzial bladder: an autoradiographic study. Cell Tissue Kinet. 12(5), 513-520 (1979).
73. Hainau B, Dombernowsky P: Histology and cell proliferation in human bladder tumors. An autoradiographic study. Cancer 33(1), 115-126 (1974).
74. Whitmore WF Jr, Batata M: Status of integrated irradiation and cystectomy for bladder cancer. Urol. Clin. N. Am. 11, 681-690 (1984).
75. Parsons JT, Million RR: Planned preoperative irradiation in the management of clinical stage B2-C (T3) bladder carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 14, 797-810 (1988).
76. Awwad HK, Baki HA, El Bolkainy, et al.: Preoperative irradiation of T3 carcinoma in Bilharzial bladder. Int. J. Radiat. Oncol. Biol. Phys. 5, 787-794 (1979).
77. Ghoneim MA, Ashamalla AG, Awwad HK, Whitmore WF Jr: Randomized trial of cystectomy with or without preoperative radiotherapy for carcinoma of the bilharzial bladder. J. Urol. 134, 266-268 (1985).
78. Blackard CE, Byar DP; VACUR Group: Results of clinical trial of surgery and radiation in stages II and III carcinoma of the bladder. J. Urol. 108, 875-878 (1972).
79. Slack NH, Bross IDJ, Prout GR: Five-year follow-up results of a collaborative study of therapies for carcinoma of the bladder. J. Surg. Oncol. 9, 393-405 (1977).
80. Anderstrom C, Johansson S, Nilsson S, et al.: A prospective randomized study of preoperative irradiation with cystectomy or cystectomy alone for invasive bladder carcinoma. Eur. Urol. 9, 142-147 (1983).
81. Smith JA, Crawford ED, Paradelo JC, et al.: Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: a Phase I II intergroup study. J. Urol. 157, 805-808 (1997).
82. Huncharek M, Muscat J, Geschwind JF: Planned preoperative radiation therapy in muscle invasive bladder cancer. Results of metaanalysis. Anticancer Res. 18, 1931-1934 (1998).
83. Reisinger S, Mohiuddin M, Mulholland S: Combined pre- and post-operative adjuvant radiation therapy for bladder cancer - a ten year experience. Int. J. Radiat. Oncol. Biol. Phys. 24, 463-468 (1992).
84. Cozzarini C, Pelegrini D, Fallini M, et al.: Reappraisal of the role of adjuvant radiotherapy in muscle-invasive transitional cell carcinoma of the bladder. Int. J. Radiat. Oncol. Biol. Phys. 45, 221 (1999).
85. El Debawy EA: Epidemiology and Results of Treatment in Operable Bladder Cancer: A retrospective Analysis. NCI Experience. MSc thesis, Faculty of Medicine Cairo University, Cairo, Egypt (2000).
86. Zaghloul MS, Mohran TZ, Saber RA, Agha N: Postoperative radiotherapy in bladder cancer. J. Egypt. Nat. Cancer Inst. 14, 161-168 (2002).
87. Zaghloul MS: Radiation as adjunctive therapy to cystectomy for bladder cancer. Is there a difference for bilharzial association? Int. J. Radiat. Oncol. Biol. Phys. 28, 783 (1994).
88. Zaghloul MS, Khaled HK, Lotyef M, William H: Adjuvant chemoradiotherapy with after radical cystectomy in advanced high risk bladder cancer patients. A prospective randomized trial. Presented at: ASCO 42th Annual Meeting. Orlando, FL, USA, 2-6 June 2006 (Abstract 4545).
89. McBain CA, Logue JP: Radiation therapy for muscle-invasive bladder cancer: treatment planning and delivery in the 21st Century. Semin. Radiat. Oncol. 15(1), 42-48 (2005).
90. Rothwell RI, Ash DV, Jones WG: Radiation treatment planning for bladder cancer: a comparison of cystogram localisation with computed tomography. Clin. Radiol. 34(1), 103-111 (1983).
91. Graham J, Gee A, Hilton S, et al.: Geometric Uncertainties in Radiotherapy of the Prostate and Bladder. British Institute of Radiology, London, UK (2003).
92. Muren LP, Smaaland R, Dahl O: Organ motion, set-up variation and treatment margins in radical radiotherapy of urinary bladder cancer. Radiother. Oncol. 69(3), 291-304 (2003).
93. Borgaonkar S, Jain A, Bollina P, et al.: Radical radiotherapy and salvage cystectomy as the primary management of transitional cell carcinoma of the bladder. Results following the introduction of a CT planning technique. Clin. Oncol. R. Coll. Radiol. 14(2), 141-147 (2002).
94. Cowan RA, McBain CA, Ryder WD, et al.: Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 59(1), 197-207 (2004).
95. McBain CA, Logue JP: Radiation therapy for muscle-invasive bladder cancer: treatment planning and delivery in the 21st Century. Semin. Radiat. Oncol. 15(1), 42-48 (2005).
96. Fokdal L, Høyer M, von der Maase H: Treatment outcome and prognostic variables for local control and survival in patients receiving radical radiotherapy for urinary bladder cancer. Acta Oncol. 43(8), 749-757 (2004).
97. Taylor A, Rockall AG, Powel ME: An atlas of the pelvic lymph node regions to aid radiotherapy target volume definition. Clin. Oncol. 19, 542-550 (2007).
98. Meijer GJ, Rasch C, Remeijer P, Lebesque JV: Three-dimensional analysis of delineation errors, setup errors, and organ motion during radiotherapy of bladder cancer. Int. J. Radiat. Oncol. Biol. Phys. 55(5), 1277-1287 (2003).
99. Søndergaard J, Høyer M, Petersen JB, et al.: The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy. Acta Oncol. 48(2), 238-244 (2009).
100. Pos FJ, Koedooder K, Hulshof MC, et al.: Influence of bladder and rectal volume on spatial variability of a bladder tumor during radical radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 55(3), 835-841 (2003).
101. Harris SJ, Buchanan RB: An audit and evaluation of bladder movements during radical radiotherapy. Clin. Oncol. R. Coll. Radiol. 10(4), 262-264 (1998).
102. Turner SL, Swindell R, Bowl N, et al.: Bladder movement during radiation therapy for bladder cancer: implications for treatment planning. Int. J. Radiat. Oncol. Biol. Phys. 39(2), 355-360 (1997).
103. Lotz HT, Pos FJ, Hulshof MC, et al.: Tumor motion and deformation during external radiotherapy of bladder cancer. Int. J. Radiat. Oncol. Biol. Phys. 64, 1551-1558 (2006).
104. McBain CA, Khoo VS, Buckley DL, et al.: Assessment of bladder motion for clinical radiotherapy practice using cine-magnetic resonance imaging. Int. J. Radiat. Oncol. Biol. Phys. 75(3), 664-671 (2009).
105. Logue JP, Sharrock CL, Cowan RA, et al.: Clinical variability of target volume description in conformal radiotherapy planning. Int. J. Radiat. Oncol. Biol. Phys. 41(4), 929-931 (1998).
106. Hanna CL, Slade S, Mason MD, Burnet NG: Accuracy of patient positioning during radiotherapy for bladder and brain tumours. Clin. Oncol. R. Coll. Radiol. 11(2), 93-98 (1999).
107. Mackie TR, Kapatoes J, Ruchala K, et al.: Image guidance for precise conformal radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 56(1), 89-105 (2003).
108. Shimizu S, Shirato H, Kitamura K, et al.: Use of an implanted marker and real-time tracking of the marker for the positioning of prostate and bladder cancers. Int. J. Radiat Oncol. Biol. Phys. 48(5), 1591-1597 (2000).
109. Hulshof MC, van Andel G, Bel A, et al.: Intravesical markers for delineation of target volume during external focal irradiation of bladder carcinomas. Radiother. Oncol. 84(1), 49-51 (2007).
110. Mangar SA, Scurr E, Huddart RA, et al.: Assessing intra-fractional bladder motion using cine-MRI as initial methodology for Predictive Organ Localization (POLO) in radiotherapy for bladder cancer. Radiother. Oncol. 85(2), 207-214 (2007).
111. van Rooijen DC, van de Kamer JB, Pool R, et al.: The effect of on-line position correction on the dose distribution in focal radiotherapy for bladder cancer. Radiat. Oncol. 4, 38 (2009).
112. Burridge N, Amer A, Marchant T, et al.: Online adaptive radiotherapy of the bladder: small bowel irradiated-volume reduction. Int. J. Radiat. Oncol. Biol. Phys. 66(3), 892-897 (2006).
113. Pos F, Remeijer P: Adaptive management of bladder cancer radiotherapy. Semin. Radiat. Oncol. 20(2), 116-120 (2010).
114. Lalondrelle S, Huddart R: Improving radiotherapy for bladder cancer: an opportunity to integrate new technologies. Clin. Oncol. R. Coll. Radiol. 21(5), 380-384 (2009).
115. Niu HT, Xu T, Zhang YB, et al.: Outcomes for a large series of radical cystectomies for bladder cancer. Eur. J. Surg. Oncol. 34(8), 911-915 (2008).
116. Manoharan M, Ayyathurai R, Soloway MS: Radical cystectomy for urothelial carcinoma of the bladder: an analysis of perioperative and survival outcome. BJU Int. 104(9), 1227-1232 (2009).
117. Ho CH, Huang CY, Lin WC, et al.: Radical cystectomy in the treatment of bladder cancer: oncological outcome and survival predictors. J. Formos. Med. Assoc. 108(11), 872-878 (2009).